SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

SOPH

Sophia Genetics
NEUTRAL
Impact 5/10
Horizonmonths Processed14d 9h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Revenue growth accelerated to 25% YoY with strong U.S. (41%) and APAC (33%) performance, and the company reiterated its path to positive adjusted EBITDA in H2 2027. Monitor Q4 revenue for FX headwind impact and the ramp of new BioPharma partnerships.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$6.91
T+0 close · Nov 3, 2026 · via day close
Latest settled
+13.75%
T+5 · $7.86 · next T+20 in 15d
Vs SPY
+14.34%
α at T+5
Latest observation
+19.89%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $6.91entry
  2. T+1 · 13d ago +0.87%α −0.78% · $6.97
  3. T+5 · 7d ago +13.75%α +14.34% · $7.86
  4. T+10 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sophia Genetics reported Q3 2026 revenue of $24.3M, up 25% YoY, beating the $24.0M consensus. GAAP EPS was -$0.24, below the consensus estimate of -$0.20, resulting in an EPS miss. The company guided full-year 2026 revenue to the upper end of its $94M-$96M range and narrowed adjusted EBITDA loss guidance to $29M-$32M, improving from $41.5M in FY 2025.

Key Financial Metrics

EPS
−$0.24
est −$0.20 · -20.0%
Revenue
$24.3M
est $24.0M · +1.1% · +25.0% YoY
Rating
miss
Guidance
$94M-$96M
maintained
Gross Margin
65.7%

Key Facts

  • Q3 2026 revenue $24.3M, up 25% YoY, above $24.0M consensus
  • GAAP EPS -$0.24 vs consensus -$0.20 (miss)
  • Adjusted EBITDA loss improved 31% YoY to $6.1M
  • Full-year 2026 revenue guided to upper end of $94M-$96M range
  • Adjusted EBITDA loss guidance $29M-$32M, improved from $41.5M in FY 2025
  • Record 118,000 analyses on SOPHiA DDM, 19% YoY volume growth
  • Net Dollar Retention increased to 118% from 108% a year ago
  • Signed 30 new core genomics customers in Q3
  • Closed three material BioPharma deals including two CDx programs and a multimodal AI project

Financial Impact

Revenue beat consensus by $0.3M (1.3%); EPS missed by $0.04 (20%); adjusted EBITDA loss improved $2.8M YoY

revenueepsadjusted_ebitda

Risk Factors

  • Foreign exchange headwinds may pressure Q4 2026 revenue
  • GAAP net loss increased 1% YoY to $20.3M
  • EPS missed consensus by 20%
  • Litigation expenses from Guardant Health lawsuits continue

Market Snapshot

Exchange
Nasdaq
Sector
Services-Computer Processing & Data Preparation
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302927003

Track record

47 reports on SOPH

Performance horizon

5 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +64.11% at T+60 after the Jun 4, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $7.45 Now $7.45 −0.00% settles Nov 25
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $7.44 Now $7.45 +0.13% settles Nov 24
  3. Nov 12, 20265d ago Insider Cluster Mixed 4/10 Entry $8.21 Now $7.45 −9.26% settles Nov 20
  4. Nov 12, 20265d ago SC 13D/A Neutral 3/10 Entry $7.86 Now $7.45 −5.22% settles Nov 19
  5. Nov 9, 20267d ago 144 Neutral 2/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
  6. Nov 9, 20268d ago Insider Cluster Bullish 4/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
  7. Nov 3, 202614d ago 6-K Neutral 5/10 No price data
  8. Nov 3, 202614d ago Press Release Neutral 5/10 Viewing Entry $6.91 to $7.86 Now $7.45 +7.81% ▲ +13.75% +14.34% vs SPY
  9. Oct 14, 20264w ago Insider Cluster Neutral 2/10 Entry $7.29 to $7.05 Now $7.45 +2.19% ▼ −3.29% −2.28% vs SPY
  10. Oct 5, 20266w ago 144 Neutral 2/10 Entry $7.38 to $7.09 Now $7.45 +0.95% ▼ −3.93% −3.79% vs SPY
Showing 10 of 47

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026